腺样囊性癌的发病分子机制研究进展  

ADVANCES IN THE MOLECULAR MECHANISM ADENOID CYSTIC CARCINOMA

作　　者：唐俊杰 施琳[1] TANG Jun-jie;SHI Lin(Inner Mongolia Medical University,Hohhot 010059 China)

机构地区：[1]内蒙古医科大学,内蒙古呼和浩特010059

出　　处：《疾病监测与控制》2018年第1期60-65,共6页Journal of Diseases Monitor and Control

基　　金：内蒙古自治区自然科学基金项目(2017MS(LH)0827)

摘　　要：腺样囊性癌(Adenoid cystic carcinoma,ACC)是第二常见唾液腺恶性肿瘤,易复发和转移,且缺乏有效的治疗措施。MYB-NFIB融合基因平衡易位是ACC的基本特征。特异性染色体易位导致MYB-NFIB融合为ACC发病提供依据,但其临床意义尚不明确。目前ACC研究很少,本综述总结ACC发病的分子机制,以求发现新型靶向药物,并进一步探索免疫治疗方法。Adenoid cystic carcinoma （ACC） is a common malignant tumor in the second salivary gland, prone to recurrence and metastasis, and lack of effective treatment. MYB-NFIB fusion gene balance translocation is the basic characteristics of ACC. Specific chromosome translocation leads to the integration of MYB-NFIB for the pathogenesis of ACC, but its clinical significance is not clear. At present, there are few ACC studies. This review summarizes the molecular mechanism of ACC morbidity in order to discover new targeted drugs and further explore the immunotherapy.

关 键 词：腺样囊腺癌 t(6 9) MYB NFIB MYB-NFIB 

分 类 号：R36[医药卫生—病理学]